Light-based therapy reduces pain associated with peripheral diabetic neuropathy, study concludes
A study conducted at the Federal University of São Paulo (UNIFESP) in Brazil has concluded that the use of monochromatic ...
Pioneering surgical approach set to pave the way for hearing loss treatment
University of Sheffield spinout company, Rinri Therapeutics, a company focused on developing new treatments for hearing loss ...
Healthline5d
How Is Shock Wave Therapy Used for Diabetic Neuropathy?
This treatment has been linked to reduced pain and overall symptom improvement for people with diabetic neuropathy. Shock wave therapy is a treatment option for diabetic neuropathy. This treatment ...
oncnursingnews4d
Topical Drug Combos May Be Beneficial for CIPN
Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect for patients undergoing cancer treatments, and ...
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...
Fox2Now St. Louis5d
Neuropathy is becoming a bigger problem for more people than ever before
At Regenerative Neuropathy, highly trained doctors are using a cutting-edge treatment and successfully slowing and often reversing the disease without addictive medications. The next 15 callers ...
KELOLAND News8d
Dynamic Spine & Neuropathy releases new book
Dr. Jeff Watson, with Dynamic Spine and Neuropathy in Sioux Falls, is a leading expert in the field of chiropractics. He recently released a groundbreaking new book titled “A Patient’s ...
GlobalData on MSN8d
Averitas completes recruitment for trial of QUTENZA to treat post-surgical pain
Averitas Pharma, the US subsidiary of Grünenthal, has completed patient recruitment for the Phase III AV001 clinical study, ...
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain
Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...